Pharmaceuticals & Life Sciences

Scotland's pharmaceutical and life sciences sector is unusually well served by published economic statistics — turnover, employment, GVA per employee, and business survival rates are tracked and published by bodies including the Fraser of Allander Institute and Scottish Development International, and the headline figures used in this article are drawn directly from that documented record. Where more interpretive caution is warranted is in assessing the sector's long-term trajectory: the strong research base and university pipeline are well documented, but whether Scotland retains enough of the resulting commercial value — as opposed to seeing successful spin-outs scale up or relocate elsewhere, particularly to England — is a matter of ongoing policy debate rather than a settled conclusion, and this article presents it as such.

Origins: a research base built over generations

Scotland's modern pharmaceutical and life sciences industry did not emerge suddenly; it rests on a biomedical and chemical research base built up over generations within the country's universities. Institutions including the University of Edinburgh, the University of Glasgow, the University of Dundee, the University of Aberdeen, and the University of Strathclyde developed deep expertise across chemistry, biomedical science, and related fields long before "life sciences" became a defined economic development priority. This academic depth gave Scotland a structural advantage when the broader UK and global pharmaceutical industry began to place greater emphasis, from the late twentieth century onward, on research-driven drug discovery and development rather than purely manufacturing scale.

Alongside this academic foundation, Scotland's longer industrial history in chemical manufacturing (detailed in this series' dedicated "The Chemical Industry" card) provided a pool of process engineering and chemical-manufacturing skill that could be redirected toward pharmaceutical production. Major international pharmaceutical companies, most notably GlaxoSmithKline (GSK), established and expanded significant manufacturing operations in Scotland, drawing directly on this combination of skilled workforce and existing chemical-industry infrastructure.

Peak scale and economic significance: a high-value, high-productivity sector

What distinguishes Scotland's pharmaceutical and life sciences sector from most of the twentieth-century industries covered elsewhere in this series is that its most significant growth is recent and ongoing rather than a historical peak followed by decline. The sector's turnover trajectory illustrates this clearly: pharmaceutical manufacturing turnover in Scotland rose from £690 million in 2019 to a pandemic-driven peak of around £2 billion, before settling at £1.65 billion in 2022 — a figure still more than double the pre-pandemic baseline, suggesting durable rather than purely temporary growth. The broader pharmaceutical sector, including research and development and medical sales activity, contributes an estimated £1.7 billion to Scottish gross value added (GVA), while the wider life sciences sector as a whole generates around £3.4 billion in GVA.

The sector's productivity figures are particularly striking. GVA per employee in Scottish pharmaceutical manufacturing reached approximately £200,700 in 2020 — more than three times the all-economy Scottish average — reflecting the high capital intensity and high-value nature of modern pharmaceutical manufacturing and research work. The sector also demonstrates strong employment multiplier effects: for every job created directly in Scottish pharmaceutical manufacturing, an estimated 1.7 further jobs are created elsewhere in the Scottish economy, and the sector directly employs around 5,900 people with a further 9,030 supported indirectly. Notably, this employment is not confined to Scotland's wealthiest urban centres: significant concentrations exist in rural areas including parts of the Highlands and in economically deprived regions such as North Ayrshire, giving the sector a genuinely national economic footprint rather than one limited to Edinburgh or Glasgow alone. Scotland's universities continue to feed this growth directly — several rank among the world's top 100, and Scotland leads the UK in STEM student enrolment relative to population, sustaining the research-to-industry pipeline that underpins the sector's continued expansion.

Ongoing status: strength, but an unresolved scaling challenge

Unlike most industries profiled in this series, pharmaceuticals and life sciences in Scotland is not a story of transformation from a mid-century peak to present-day decline — it remains, by most available measures, a genuinely growing sector. This does not mean the sector is without structural challenges. A recurring theme in sector commentary and economic analysis (including reporting from the Fraser of Allander Institute) is the difficulty of converting Scotland's strong research base and promising early-stage spin-out companies into large, independently Scottish-headquartered pharmaceutical or biotech firms capable of competing globally at full scale. There is a documented pattern of successful Scottish-origin companies and talent relocating, partially or fully, to England or further afield once they require the scale of capital, talent pools, or regulatory proximity that larger markets offer — though the extent to which this represents an avoidable policy failure versus an inevitable feature of how global life sciences capital markets function is genuinely debated rather than agreed.

Business survival rates offer one point of genuine reassurance: life sciences businesses in Scotland show a 67% survival rate compared with 57% for the broader Scottish economy, suggesting the sector's companies, once established, are more durable than the Scottish business population as a whole, even if scaling to global significance remains harder to achieve consistently.

Present-day legacy and role in the modern economy

Today, pharmaceuticals represent Scotland's second-largest contributor to business research and development spending, reflecting the sector's centrality to Scotland's broader ambitions around a knowledge-based, high-value economy — a marked contrast to the heavy-industry and manufacturing-volume-driven sectors that dominated earlier chapters of Scottish industrial history covered throughout this series. The sector's close integration with NHS Scotland, which provides both a research partner and a genuine route to clinical trial and adoption pathways for new treatments, is frequently cited as a distinctive structural strength relative to life sciences clusters elsewhere. Whether Scotland can continue converting its research excellence into a larger, more self-sustaining commercial ecosystem — rather than one that periodically exports its most successful companies and talent southward — remains the central open question shaping how this still-growing industry's next chapter will be written.

• Scottish pharmaceutical manufacturing turnover briefly approached £2 billion during the COVID-19 pandemic, before settling at a still-elevated £1.65 billion in 2022 — well above its 2019 baseline of £690 million.
• GVA per employee in Scotland's pharmaceutical sector is more than triple the Scottish all-economy average, making it one of the most productive industries in the country by this measure.
• For every job created directly in Scottish pharmaceutical manufacturing, an estimated 1.7 further jobs are supported elsewhere in the Scottish economy.
• Significant pharmaceutical and life sciences employment exists outside Scotland's main cities, including in rural Highlands locations and in North Ayrshire, one of Scotland's more economically deprived areas.
• Scottish life sciences businesses have a notably higher survival rate (67%) than the Scottish business population as a whole (57%).
• Pharmaceuticals rank as Scotland's second-largest sector by business research and development spending, reflecting the industry's knowledge-intensive character.
• Scotland's life sciences cluster is frequently described as one of the larger such clusters in Europe, despite the country's relatively small population.
• A persistent challenge noted by economic analysts is that promising Scottish life sciences spin-out companies sometimes relocate south as they scale, a pattern that remains a live policy concern rather than a solved problem.

• Do not present Scotland's life sciences sector as unambiguously converting research strength into large-scale commercial success — correct phrasing acknowledges the debated, unresolved challenge of retaining scaling companies and talent within Scotland.
• Do not treat sector-promotional descriptions (e.g. "flagship industry") as neutral economic fact without noting their promotional origin — correct phrasing distinguishes documented statistics from favourable sector framing.
• Do not imply the sector is a direct continuation of Scotland's historic explosives/dyestuffs chemical industry — correct phrasing notes meaningful but partial workforce/infrastructure continuity, with the modern sector substantially university-research-driven and distinct in character.
• Avoid presenting the pandemic-era turnover peak (~£2 billion) as the sector's "normal" ongoing scale — correct phrasing notes the 2022 figure of £1.65 billion as the more representative recent baseline.